ERBB2 and breast carcinoma: The American Society of Clinical Oncology (ASCO) guideline for HER2-positive advanced/metastatic breast cancer trastuzumab treatment is to continue HER2-targeted therapy without change unless there is progression or unacceptable toxicities [6].